What does the evidence say about Bifidobacterium Breve Cognition Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Bifidobacterium Breve Cognition Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - The pooled Repeatable Battery for the Assessment of Neuropsychological Status result was not statistically significant ( g = 0.46; 95% CI: -0.50 to 1.41). [Silva-Olivares F (2026); evidence level 1] - Discussion Live microorganism-based interventions showed preliminary short-term functional signals, but the small evidence base, high cognitive heterogeneity, short follow-up, and sensitivity to individual studies preclude firm efficacy conclusions. [Silva-Olivares F (2026); evidence level 1] - No eligible fecal microbiota transplantation trial was identified, so the evidence derives exclusively from probiotic and synbiotic studies. [Silva-Olivares F (2026); evidence level 1] - Introduction Preserving cognitive and physical function is central to healthy aging, and the gut microbiota may influence both brain and muscle physiology. [Silva-Olivares F (2026); evidence level 1] - There is mounting evidence that the gut microbiome (GM) and microbial dysbiosis contribute to the common mental health and neurocognitive disorders, including anxiety, bipolar disorder, obsessive‐compulsive disorder, and dementia, via the gut‐brain axis (GBA). [Mandloi Nidhi (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.